Moexipril. A review of its use in the management of essential hypertension

Drugs

Volumn 55, Issue 6, 1998, Pages 845-860

  Brogden, Rex N ^a   Wiseman, Lynda R ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELECTROLYTE; GLUCOSE; HYDROCHLOROTHIAZIDE; LIPID; METOPROLOL; MOEXIPRIL; NITRENDIPINE; PRODRUG; VERAPAMIL;

ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG HYDROLYSIS; ELECTROLYTE METABOLISM; ESSENTIAL HYPERTENSION; GLUCOSE METABOLISM; HEADACHE; HUMAN; LIPID METABOLISM; META ANALYSIS; UPPER RESPIRATORY TRACT INFECTION;

AGE FACTORS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; ISOQUINOLINES; MALE; PRODRUGS; RANDOMIZED CONTROLLED TRIALS; TETRAHYDROISOQUINOLINES;

EID: 0031832717     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855060-00018     Document Type: Article

References (46)

1. Friehe H, Ney P. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride. Arzneimittel Forschung 1997 Feb; 47: 132-44
2. Edling O, Bao G, Feelisch M, et al. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther 1995 Nov: 275: 854-63
3. White WB, Whelton A, Fox AAL, et al. Tricenter assessment of the efficacy of the ACE inhibitor, moexipril, by ambulatory blood pressure monitoring. J Clin Pharmacol 1995 Mar; 35: 233-8
4. Lucas CP, Darga LL, Fox AAL, et al. A study of the efficacy and safety of moexipril in mild to moderate hypertension. Am J Ther 1995 Nov; 2: 886-92
5. Mroczek WJ, Stimpel M. A double-blind evaluation of moexipril versus hydrochlorothiazide in hypertension. Adv Ther 1996 Mar-Apr; 13: 79-87
6. Persson B, Stimpel M. Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients. Eur J Clin Pharmacol 1996 Jun; 50: 259-64
7. Stimpel M, Bonn R, Koch B, et al. Pharmacology and clinical use of the new ACE-inhibitor moexipril. Cardiovasc Drug Rev 1995; 13 (3): 211-29
8. White WB, Fox AAL, Stimpel M. Long-term efficacy and safety of moexipril in the treatment of hypertension. J Hum Hypertens 1994 Dec; 8: 917-21
9. Stimpel M, Jee WSS, Liang H, et al. Antihypertensive therapy and postmenopausal osteoporosis: skeletal effects of mono-and combination-therapy of moexipril and hydrochlorothiazide in ovariectomized spontaneously hypertensive rats (SHR) [abstract]. Am J Hypertens 1997 Apr; 10: 156A
10. Stimpel M, Jee WSS, Ma Y, et al. Impact of antihypertensive therapy on postmenopausal osteoporosis: effects of the ace-inhibitor moexipril, estrogen and their combination on the prevention of the ovariectomy (OVX)-induced cancellous bone loss in young rats [abstract]. 7th European Meeting on Hypertension 1995 Jun 9: 186
11. Stimpel M, Jee WSS, Ma Y, et al. ACE-inhibition and osteoporosis: moexipril alone or in combination with estrogen in the treatment of ovariectomy (postmenopausal)-induced osteoporosis in rats [abstract]. Hypertension 1995 Jun; 25: 1406
12. Stimpel M, Jee WSS, Ma Y, et al. Impact of antihypertensive therapy on postmenopausal osteoporosis: effects of the angiotensin converting enzyme inhibitor moexipril, 17-β-estradiol and their combination on the ovariectomy-induced cancellous bone loss in young rats. J Hypertens 1995 Dec; 13 (Pt 2): 1852-6
13. Hatton R, Stimpel M, Chambers TJ. Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro. J Endocrinol 1997; 152: 5-10
14. Stauss HM, Zhu YC, Redlich T, et al. Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. J Cardiovasc Risk 1994 Oct; 1: 255-62
15. Grohé C, Kahlert S, Löbbert K, et al. Effects of moexiprilat on oestrogen-stimulated cardiac fibroblast growth. Br J Pharmacol 1997; 121: 1-5
16. Perico N, Amuchastegui SC, Colosio V, et al. Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. J Am Soc Nephrol 1994 Oct; 5: 1139-46
17. Rosenkranz RP, Hayashi CM, Lakatos I, et al. Diuretic effects of an ACE inhibitor, RS-10085, and hydrochlorothiazide in the spontaneously hypertensive rat. Proc West Pharmacol Soc 1989; 32: 221-5
18. Hammes W, Hammes B, Büchsler U, et al. Simultaneous determination of moexipril and moexiprilat, its active metabolite, in human plasma by gas chromatography-negative-ion chemical ionization mass spectrometry. J Chromatogr B Biomed Appl 1995 Aug 4; 670: 81-9
19. Grass GM, Morehead WT. Evidence for site-specific absorption of a novel ACE inhibitor. Pharm Res 1989 Sep; 6: 759-65
20. Stimpel M, Cawello W. Pharmacokinetics and ACE-inhibition of the new ACE-inhibitor moexipril: is coadministration with food of clinical relevance? [abstract]. Hypertension 1995 Jun; 25: 1384
21. Study report GHBA 628. Schwarz Pharma AG. 1997. (Data on file)
22. Todd PA, Benefield P. Ramipril: a review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 1990; 39: 110-35
23. Stimpel M, Koch B, Jansen T, et al. Moexipril versus captopril in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1996 Dec; 28: 769-73
24. Stimpel M, Koch B, Moexipril for H in PWSPI. Antihypertensive treatment in postmenopausal women with hypertension and obesity: moexipril versus atenolol [abstract]. Am J Hypertens 1996 Apr; 9 (Pt 2): 175A
25. Stimpel M, Koch B. Antihypertensive treatment with moexipril plus HCTZ vs metoprolol plus HCTZ in patients with mild-to-moderate hypertension. J Hum Hypertens 1997 Feb; 11: 133-7
26. Abernethy DR, Fox AA, Stimpel M. Moexipril in the treatment of mild to moderate essential hypertension: comparison with sustained-release verapamil. J Clin Pharmacol 1995 Aug; 35: 794-9
27. Chrysant SG, Stimpel M. A comparison of the antihypertensive effectiveness of a combination of moexipril or sustained-release verapamil with low-dose hydrochlorothiazide. J Clin Pharmacol 1996 Aug; 36: 701-6
28. Prüsse D-I, Stimpel M. Investigators of the MADAM programme. Blood pressure response and safety profile of moexipril and nitrendipine in postmenopausal, hypertensive women [abstract]. Hypertension 1997 Mar; 29: 844
29. Stimpel M, Koch B, Oparil S. Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide). Cardiology, in press
30. Stimpel M, Koch B, MADAM programme. A comparative trial of moexipril versus hydrochlorothiazide in postmenopausal women with hypertension: results from the MADAM Program [abstract]. 2nd International Symposium on Women's Health and Menopause Risk Reduction Strategies 1996 Dec 4-7 Florence, Italy: 60
31. Drayer JIM, Stimpel M, Fox A, et al. The antihypertensive properties of the angiotensin-converting enzyme inhibitor moexipril given alone or in combination with a low dose of a diuretic. Am J Ther 1995 Aug; 2: 525-31
32. White WB, Koch B, Stimpel M. Usefulness of moexipril and hydrochlorothiazide in moderately severe essential hypertension. Am J Ther 1997 Apr; 4: 123-9
33. Dickstein K, Aarsland T, Ferrari P, et al. Comparison of the efficacy of three dose levels of moexipril versus placebo as add-on therapy to hydrochlorothiazide in patients with moderate hypertension. J Cardiovasc Pharmacol 1994 Aug; 24: 247-55
34. Stimpel M, Koch B, Dickstein K. Moexipril as add-on therapy to hydrochlorothiazide in moderate to severe hypertension. Cardiology 1996 Jul-Aug; 87: 313-8
35. Koch B, Stimpel M. Low-dose combination of moexipril and HCTZ: an option in antihypertensive treatment [abstract]. Hypertension 1997 Mar; 29: 867
36. Koch B, Stimpel M. Low-dose combination of moexipril and HCTZ: an option in antihypertensive treatment [abstract]. Am J Hypertens 1996 Apr; 9: 159
37. Koch B, Stimpel M. Do hypertensive women respond differently to low dosages of moexipril and hydrochlorothiazide? [abstract]. Hypertension 1995 Jun; 25: 1383
38. Chrysant SG, Stimpel M. Antihypertensive effectiveness of a very low fixed-dose combination of moexipril and hydrochlorothiazide. J Cardiovasc Pharmacol 1998; 31: 384-90
39. Persson B, Widgren BR, Fox A, et al. Antihypertensive effects of moexipril, a new ACE inhibitor, as add-on therapy to nifedipine in patients with essential hypertension. J Cardiovasc Pharmacol 1995 Jul; 26: 73-8
40. White WB, Stimpel M. Long-term safety and efficacy of moexipril alone and in combination with hydrochlorothiazide in elderly patients with hypertension. J Hum Hypertens 1995 Nov; 9: 879-84
41. Stimpel M. Moexipril. In: Messerli FH, editor. Cardiovascular drug therapy. 2nd ed. Philadelphia: Saunders, 1996: 813-6
42. Stimpel M, Koch B, MADAM programme. Antihypertensive treatment of obese postmenopausal women: ACE-inhibitor or beta-blocker? [abstract]. 2nd International Symposium on Women's Health and Menopause Risk Reduction Strategies 1996 Dec 4-7 Florence, Italy: 61
43. Stimpel M, Koch B. Investigators of the MADAM programme. Moexipril versus placebo in postmenopausal women receiving HRT [abstract]. Hypertension 1997 Mar; 29: 843
44. Koch B, Oparil S, Stimpel M. Co-administration of an ACE inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women. Schwarz Pharma AG, Monhein, Germany. (Data on file)
45. Kannel WB, Hjortland MC, McNamara PM, et al. Menopause and risk of cardiovascular disease. The Framingham study. Ann Intern Med 1976; 85: 447-52
46. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997 Nov 24; 157: 2413-46